Literature DB >> 3572041

Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides.

D E Briles, G Scott, B Gray, M J Crain, M Blaese, M Nahm, V Scott, P Haber.   

Abstract

Naturally occurring antibodies reactive with the phosphocholine (PC) determinant of pneumococcal teichoic acids may be useful for evaluating the potential of patients to make antibodies to polysaccharides. Antibodies to PC are present in most adults under the age of 60 years, are absent in very young children, and are present at low levels in Wiscott-Aldrich patients and in IgG2-deficient adults. These last three groups respond very poorly to polysaccharide antigens. Antibodies to PC are also found at low levels in the elderly, a group that has previously been shown to have low levels of antibody to blood groups A and B carbohydrates. The levels of antibody to PC over time were constant in most individuals and, in adults, seemed to show slightly less variation than did titers of antibody to blood group B. Our findings suggest that titers of antibody to PC may be superior to titers of antibody to blood group A or B for monitoring responsiveness to carbohydrate antigens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572041     DOI: 10.1093/infdis/155.6.1307

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Opsonization of Actinobacillus actinomycetemcomitans by immunoglobulin G antibody reactive with phosphorylcholine.

Authors:  Donald Purkall; John G Tew; Harvey A Schenkein
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Pneumococcal antigens and serum antibody responses in experimentally induced sinusitis.

Authors:  K M Westrin; A Freijd; P Stierna
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

3.  Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae.

Authors:  J N Weiser; M Shchepetov; S T Chong
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 4.  Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases.

Authors:  Harvey A Schenkein; Bruno G Loos
Journal:  J Clin Periodontol       Date:  2013-04       Impact factor: 8.728

5.  Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract.

Authors:  E S Lysenko; J Gould; R Bals; J M Wilson; J N Weiser
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

6.  Specificity of human antibodies reactive with pneumococcal C polysaccharide.

Authors:  C E Frasch; N F Concepcion
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

7.  Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

Authors:  Martina M Ochs; William Bartlett; David E Briles; Bryony Hicks; Audra Jurkuvenas; Peggy Lau; Bing Ren; Amanda Millar
Journal:  Microb Pathog       Date:  2007-10-11       Impact factor: 3.738

8.  Altered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (FcμR).

Authors:  Kazuhito Honjo; Yoshiki Kubagawa; Dewitt M Jones; Brian Dizon; Zilu Zhu; Hiroshi Ohno; Shozo Izui; John F Kearney; Hiromi Kubagawa
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

9.  Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine.

Authors:  Reshmi Mukerji; Shaper Mirza; Aoife M Roche; Rebecca W Widener; Christina M Croney; Dong-Kwon Rhee; Jeffrey N Weiser; Alexander J Szalai; David E Briles
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

Review 10.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.